vs

Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $134.9M, roughly 1.7× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 19.4%, a 63.2% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 55.1%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 43.2%).

Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CTRE vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.7× larger
ORGO
$225.6M
$134.9M
CTRE
Growing faster (revenue YoY)
ORGO
ORGO
+23.0% gap
ORGO
78.1%
55.1%
CTRE
Higher net margin
CTRE
CTRE
63.2% more per $
CTRE
82.5%
19.4%
ORGO
Faster 2-yr revenue CAGR
CTRE
CTRE
Annualised
CTRE
46.2%
43.2%
ORGO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTRE
CTRE
ORGO
ORGO
Revenue
$134.9M
$225.6M
Net Profit
$111.3M
$43.7M
Gross Margin
Operating Margin
28.1%
Net Margin
82.5%
19.4%
Revenue YoY
55.1%
78.1%
Net Profit YoY
113.5%
469.5%
EPS (diluted)
$0.52
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRE
CTRE
ORGO
ORGO
Q4 25
$134.9M
$225.6M
Q3 25
$132.4M
$150.9M
Q2 25
$112.5M
$101.0M
Q1 25
$96.6M
$86.7M
Q4 24
$86.9M
$126.7M
Q3 24
$77.4M
$115.2M
Q2 24
$68.9M
$130.2M
Q1 24
$63.1M
$110.0M
Net Profit
CTRE
CTRE
ORGO
ORGO
Q4 25
$111.3M
$43.7M
Q3 25
$74.9M
$21.6M
Q2 25
$68.5M
$-9.4M
Q1 25
$65.8M
$-18.8M
Q4 24
$52.1M
$7.7M
Q3 24
$33.4M
$12.3M
Q2 24
$10.8M
$-17.0M
Q1 24
$28.7M
$-2.1M
Gross Margin
CTRE
CTRE
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
CTRE
CTRE
ORGO
ORGO
Q4 25
28.1%
Q3 25
58.1%
13.7%
Q2 25
61.3%
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
43.0%
5.4%
Q2 24
15.1%
-10.7%
Q1 24
-3.5%
Net Margin
CTRE
CTRE
ORGO
ORGO
Q4 25
82.5%
19.4%
Q3 25
56.6%
14.3%
Q2 25
60.9%
-9.3%
Q1 25
68.1%
-21.7%
Q4 24
60.0%
6.1%
Q3 24
43.2%
10.7%
Q2 24
15.6%
-13.1%
Q1 24
45.6%
-1.9%
EPS (diluted)
CTRE
CTRE
ORGO
ORGO
Q4 25
$0.52
$0.31
Q3 25
$0.35
$0.11
Q2 25
$0.35
$-0.10
Q1 25
$0.35
$-0.17
Q4 24
$0.30
$0.05
Q3 24
$0.21
$0.09
Q2 24
$0.07
$-0.13
Q1 24
$0.22
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRE
CTRE
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$198.0M
$93.7M
Total DebtLower is stronger
$894.2M
Stockholders' EquityBook value
$4.0B
$300.1M
Total Assets
$5.1B
$598.7M
Debt / EquityLower = less leverage
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRE
CTRE
ORGO
ORGO
Q4 25
$198.0M
$93.7M
Q3 25
$712.5M
$63.7M
Q2 25
$306.1M
$73.1M
Q1 25
$26.5M
$110.0M
Q4 24
$213.8M
$135.6M
Q3 24
$377.1M
$94.3M
Q2 24
$495.1M
$89.9M
Q1 24
$451.2M
$88.6M
Total Debt
CTRE
CTRE
ORGO
ORGO
Q4 25
$894.2M
Q3 25
$893.8M
Q2 25
$1.2B
Q1 25
$822.1M
Q4 24
$396.9M
Q3 24
$396.7M
$62.3M
Q2 24
$671.1M
$63.8M
Q1 24
$595.9M
$65.2M
Stockholders' Equity
CTRE
CTRE
ORGO
ORGO
Q4 25
$4.0B
$300.1M
Q3 25
$4.0B
$255.1M
Q2 25
$3.3B
$233.2M
Q1 25
$2.9B
$242.9M
Q4 24
$2.9B
$262.9M
Q3 24
$2.4B
$278.5M
Q2 24
$1.9B
$263.5M
Q1 24
$1.7B
$278.0M
Total Assets
CTRE
CTRE
ORGO
ORGO
Q4 25
$5.1B
$598.7M
Q3 25
$5.1B
$509.8M
Q2 25
$4.7B
$461.1M
Q1 25
$3.9B
$467.4M
Q4 24
$3.4B
$497.9M
Q3 24
$2.9B
$446.3M
Q2 24
$2.7B
$443.2M
Q1 24
$2.3B
$458.5M
Debt / Equity
CTRE
CTRE
ORGO
ORGO
Q4 25
0.22×
Q3 25
0.22×
Q2 25
0.35×
Q1 25
0.28×
Q4 24
0.14×
Q3 24
0.16×
0.22×
Q2 24
0.35×
0.24×
Q1 24
0.36×
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRE
CTRE
ORGO
ORGO
Operating Cash FlowLast quarter
$394.0M
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
3.54×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRE
CTRE
ORGO
ORGO
Q4 25
$394.0M
$39.4M
Q3 25
$100.9M
$3.1M
Q2 25
$100.8M
$-32.9M
Q1 25
$71.4M
$-19.9M
Q4 24
$244.3M
$10.9M
Q3 24
$67.2M
$8.7M
Q2 24
$53.0M
$4.7M
Q1 24
$48.8M
$-10.2M
Free Cash Flow
CTRE
CTRE
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
CTRE
CTRE
ORGO
ORGO
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
CTRE
CTRE
ORGO
ORGO
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
CTRE
CTRE
ORGO
ORGO
Q4 25
3.54×
0.90×
Q3 25
1.35×
0.14×
Q2 25
1.47×
Q1 25
1.08×
Q4 24
4.68×
1.43×
Q3 24
2.01×
0.71×
Q2 24
4.92×
Q1 24
1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons